Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Y. H. | - |
dc.contributor.author | Woo, J-H | - |
dc.contributor.author | Choi, S. J. | - |
dc.contributor.author | Ji, J. D. | - |
dc.contributor.author | Bae, S-C | - |
dc.contributor.author | Song, G. G. | - |
dc.date.accessioned | 2021-09-08T01:12:19Z | - |
dc.date.available | 2021-09-08T01:12:19Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-08 | - |
dc.identifier.issn | 0300-9742 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115957 | - |
dc.description.abstract | Objective. The aim of this study was to assess the efficacy and safety of tacrolimus in patients with active rheumatoid arthritis (RA). Methods. We surveyed randomized controlled trials (RCTs) and open-label studies that examined the efficacy and toxicity of tacrolimus in disease-modifying anti-rheumatic drug (DMARD) - and methotrexate (MTX)-resistant or intolerant patients with active RA patients using Medline, the Cochrane Controlled Trials Register, and by performing manual searches. Meta-analysis of RCTs was performed to determine treatment efficacy and safety outcomes. The results are presented as risk ratios (RRs), weighted mean differences (WMDs), or standardized mean differences (SMDs). Open-label studies were included in the systematic review. Results. The four RCTs included 1014 DMARD-resistant or -intolerant patients with DMARD-resistant or -intolerant RA. Median follow-up duration was 6 (range 4-6) months. American College of Rheumatology 20, 50, and 70% (ACR20, ACR50, and ACR70) response rates were significantly higher in the tacrolimus 3 mg/day group (n = 390) than in the controls (n = 402) [primary efficacy outcome, ACR50; risk ratio (RR) 2.583, 95% confidence interval (CI) 1.095-6.092, p = 0.030], and efficacies in the tacrolimus 1.5-2 mg/day group showed a similar pattern. Patients treated with tacrolimus withdrew from treatment because of adverse events (n = 222) (primary safety outcome, withdrawals due to adverse events; RR 1.475, 95% CI 0.895-2.187, p = 0.053) more frequently than controls (n = 231), although this was not significant. All four open-label studies found that tacrolimus was safe, well-tolerated, and provided clinical benefits. Conclusions. Tacrolimus, at dosages of 1.5-3 mg/day, was found to be effective in DMARD-resistant or -intolerant patients with active RA. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | SAFETY | - |
dc.subject | METHOTREXATE | - |
dc.subject | EFFICACY | - |
dc.subject | FK506 | - |
dc.subject | 6-MONTH | - |
dc.subject | DISEASE | - |
dc.subject | FK-506 | - |
dc.title | Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Y. H. | - |
dc.contributor.affiliatedAuthor | Choi, S. J. | - |
dc.contributor.affiliatedAuthor | Ji, J. D. | - |
dc.contributor.affiliatedAuthor | Song, G. G. | - |
dc.identifier.doi | 10.3109/03009740903501642 | - |
dc.identifier.scopusid | 2-s2.0-77954879792 | - |
dc.identifier.wosid | 000281388000001 | - |
dc.identifier.bibliographicCitation | SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, v.39, no.4, pp.271 - 278 | - |
dc.relation.isPartOf | SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | - |
dc.citation.title | SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | - |
dc.citation.volume | 39 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 271 | - |
dc.citation.endPage | 278 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | FK506 | - |
dc.subject.keywordPlus | 6-MONTH | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | FK-506 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.